These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 26364391)

  • 1. [Basal insulin and liraglutide combined in a pen].
    Rausch R
    Med Monatsschr Pharm; 2015 Apr; 38(4):154-6. PubMed ID: 26364391
    [No Abstract]   [Full Text] [Related]  

  • 2. Insulin and GLP-1 analog combinations in type 2 diabetes mellitus: a critical review.
    Jendle J; Martin SA; Milicevic Z
    Expert Opin Investig Drugs; 2012 Oct; 21(10):1463-74. PubMed ID: 22799463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can a fixed-ratio combination of insulin degludec and liraglutide help Type 2 diabetes patients to optimize glycemic control across the day?
    Simpson R; King A
    Expert Rev Clin Pharmacol; 2015 Mar; 8(2):179-88. PubMed ID: 25697410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hormone copycats.
    Gebel E
    Diabetes Forecast; 2012 Jun; 65(6):36, 38-9. PubMed ID: 22737769
    [No Abstract]   [Full Text] [Related]  

  • 5. Exenatide for once-weekly administration.
    Drug Ther Bull; 2012 Jul; 50(7):78-80. PubMed ID: 22789767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination therapy with liraglutide and sulfonylurea for a type 2 diabetic patient with high titer of anti-insulin antibodies produced by insulin therapy.
    Yoshida M; Asai M; Miyata M; Ogawa K; Maeda H; Oiso Y
    Diabetes Res Clin Pract; 2012 Jun; 96(3):e55-6. PubMed ID: 22257418
    [No Abstract]   [Full Text] [Related]  

  • 7. Using prandial insulin to achieve glycemic control in type 2 diabetes.
    Dailey GE
    J Fam Pract; 2007 Sep; 56(9):735-42. PubMed ID: 17764645
    [No Abstract]   [Full Text] [Related]  

  • 8. Subcutaneous administration of liraglutide ameliorates Alzheimer-associated tau hyperphosphorylation in rats with type 2 diabetes.
    Yang Y; Zhang J; Ma D; Zhang M; Hu S; Shao S; Gong CX
    J Alzheimers Dis; 2013; 37(3):637-48. PubMed ID: 23948890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attempted suicide with liraglutide overdose did not induce hypoglycemia.
    Nakanishi R; Hirose T; Tamura Y; Fujitani Y; Watada H
    Diabetes Res Clin Pract; 2013 Jan; 99(1):e3-4. PubMed ID: 23149376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An analysis of dosage volume for halfway doses in the Victoza Pen.
    Kroon L
    J Diabetes Sci Technol; 2011 Nov; 5(6):1625-6. PubMed ID: 22226290
    [No Abstract]   [Full Text] [Related]  

  • 11. Accuracy of dosage volume for halfway doses in the Victoza Pen.
    King AB; Wolfe GS
    J Diabetes Sci Technol; 2011 Nov; 5(6):1623-4. PubMed ID: 22226289
    [No Abstract]   [Full Text] [Related]  

  • 12. Liraglutide-induced acute pancreatitis.
    Jeyaraj S; Shetty AS; Kumar CR; Nanditha A; Krishnamoorthy S; Raghavan A; Raghavan K; Ramachandran A
    J Assoc Physicians India; 2014 Jan; 62(1):64-6. PubMed ID: 25327099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term liraglutide treatment is associated with increased insulin content and secretion in β-cells, and a loss of α-cells in ZDF rats.
    Schwasinger-Schmidt T; Robbins DC; Williams SJ; Novikova L; Stehno-Bittel L
    Pharmacol Res; 2013 Oct; 76():58-66. PubMed ID: 23891763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Which incretin-based therapy for type 2 diabetes?
    Scheen AJ
    Lancet; 2014 Oct; 384(9951):1325-7. PubMed ID: 25018117
    [No Abstract]   [Full Text] [Related]  

  • 15. Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes.
    Courrèges JP; Vilsbøll T; Zdravkovic M; Le-Thi T; Krarup T; Schmitz O; Verhoeven R; Bugáñová I; Madsbad S
    Diabet Med; 2008 Sep; 25(9):1129-31. PubMed ID: 19183322
    [No Abstract]   [Full Text] [Related]  

  • 16. An overview of the pharmacokinetics, efficacy and safety of liraglutide.
    Bode B
    Diabetes Res Clin Pract; 2012 Jul; 97(1):27-42. PubMed ID: 22245694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liraglutide treatment in a patient with HIV, type 2 diabetes and sleep apnoea-hypopnoea syndrome.
    García de Lucas MD; Olalla Sierra J; Piña Fernández J
    Diabetes Metab; 2015 Feb; 41(1):102-3. PubMed ID: 25455831
    [No Abstract]   [Full Text] [Related]  

  • 18. [Optimizing treatment of type 2 diabetic patients].
    Red
    MMW Fortschr Med; 2015 Jun; 157(11):64. PubMed ID: 26049358
    [No Abstract]   [Full Text] [Related]  

  • 19. Challenges and strategies for moving patients to injectable medications.
    Siminerio L
    Diabetes Educ; 2006; 32 Suppl 2():82S-90S. PubMed ID: 16554432
    [No Abstract]   [Full Text] [Related]  

  • 20. Next-generation GLP-1 therapy: an introduction to liraglutide.
    Repas T
    Postgrad Med; 2011 Sep; 123(5):239-47. PubMed ID: 21904107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.